AstraZeneca, Daiichi's Trodelvy rival fails to improve overall survival in breast cancer trial
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival (OS) in a phase 3 trial. The latest miss happened in breast cancer, a setting in which Gilead’s rival Trodelvy significantly improved OS in a prior late-phase study.
The partners said their antibody-drug conjugate datopotomab deruxtecan didn’t extend survival in a breast cancer study, ...
Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...
A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...
Discover Daiichi Sankyo's groundbreaking patent for monoclonal antibodies targeting LAG-3, offering new hope for treating autoimmune diseases with enhanced efficacy.
As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...
Daiichi Sankyo has launched a new direct-to-consumer (DTC) campaign for Enhertu — the first DTC effort for its oncology unit ...
GlobalData on MSN4d
NHS England to offer Daiichi Sankyo’s quizartinib for AMLThe UK Medicines and Healthcare products Regulatory Agency previously confirmed the asset’s safety and efficacy.
ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.
NICE has recommended Vanflyta (quizartinib) for routine NHS commissioning as an induction, consolidation, and maintenance ...
No longer a far-off futuristic idea, artificial intelligence technology has seen its popularity skyrocket in recent years. | ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback